Allianz Asset Management GmbH Reduces Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Allianz Asset Management GmbH decreased its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 22.2% during the first quarter, according to its most recent filing with the SEC. The firm owned 92,233 shares of the biopharmaceutical company's stock after selling 26,347 shares during the period. Allianz Asset Management GmbH owned 0.16% of Agios Pharmaceuticals worth $2,702,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in AGIO. GF Fund Management CO. LTD. purchased a new position in shares of Agios Pharmaceuticals in the 4th quarter worth approximately $39,000. CWM LLC boosted its stake in Agios Pharmaceuticals by 150.2% in the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 996 shares in the last quarter. Sterling Capital Management LLC boosted its stake in Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after purchasing an additional 1,587 shares in the last quarter. Summit Investment Advisors Inc. boosted its stake in Agios Pharmaceuticals by 7.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock worth $194,000 after purchasing an additional 394 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in Agios Pharmaceuticals by 9,296.6% in the 1st quarter. GAMMA Investing LLC now owns 8,175 shares of the biopharmaceutical company's stock worth $240,000 after purchasing an additional 8,088 shares in the last quarter.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 11,914 shares of the business's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $37.99, for a total value of $452,612.86. Following the completion of the sale, the insider owned 61,271 shares of the company's stock, valued at approximately $2,327,685.29. The trade was a 16.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Tsveta Milanova sold 2,770 shares of the business's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total transaction of $92,905.80. Following the completion of the sale, the insider directly owned 26,122 shares of the company's stock, valued at approximately $876,131.88. The trade was a 9.59% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 46,363 shares of company stock worth $1,619,654. Insiders own 4.30% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on AGIO. Bank of America decreased their price objective on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. Wall Street Zen cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Finally, Scotiabank decreased their price objective on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a research note on Monday, July 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $56.33.

Agios Pharmaceuticals Stock Performance

Shares of AGIO traded down $2.22 during trading hours on Friday, hitting $35.00. The stock had a trading volume of 2,351,119 shares, compared to its average volume of 723,031. The firm has a 50-day moving average price of $35.69 and a 200 day moving average price of $32.57. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of 3.18 and a beta of 0.80.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.74) by ($0.19). Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.39%. The firm had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.46 million. As a group, analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.